A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-κB pathways

Bromodomain-containing protein 4 (BRD4) has emerged as a promising treatment target for bone-related disorders. (+)-JQ1, a thienotriazolodiazepine compound, has been shown to inhibit pro-osteoclastic activity in a BRD4-dependent approach and impede bone loss caused by ovariectomy (OVX) in vivo. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ying, Liu, Wenjie, Yu, Ziqiang, Zhang, Yan, Li, Yinghua, Xie, Dantao, Xie, Gang, Fan, Li, He, Shipeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236062/
https://www.ncbi.nlm.nih.gov/pubmed/34175898
http://dx.doi.org/10.1038/s41419-021-03939-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236062/
https://www.ncbi.nlm.nih.gov/pubmed/34175898
http://dx.doi.org/10.1038/s41419-021-03939-7

Ejemplares similares